Evidence map›Paper›PMID 41796401›Full record

ArticleDiscover oncology2026

DENND2D serves as a novel prognostic biomarker with paradoxical protumorigenic effects in glioma.

Hongxing Ye, Chao Zhang, Linghao Bu, Feng Xiao, Yuxiang Weng, Kaiyuan Huang, Zebin Fang, Weijian Fan, Hao Jiang, Yu Zhu and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hongxing YeDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Chao ZhangDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Linghao BuDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Feng XiaoDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Yuxiang WengDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Kaiyuan HuangDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Zebin FangDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Weijian FanDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Hao JiangDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Yu ZhuDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Renya ZhanDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Xiujue ZhengDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Yumin WangDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China.
Zhouying PengDepartment of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China. zypeng@csu.edu.cn.
Luyuan ZhangDepartment of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. 1320110@zju.edu.cn.

Funding

Zhejiang Provincial Natural Science Foundation of China LY18H160020
6 · The paper itself

Abstract

introductionGlioma, especially glioblastoma (GBM), has a dismal prognosis with current therapies. In this study, we aimed to identify potential novel molecular targets for GBM by analyzing RNA sequencing.

methodsRNA-seq data from TCGA, CGGA, and GTEx were analyzed to assess DENND2D expression across glioma grades and molecular subtypes. Survival analysis, methylation/copy number profiling, weighted gene co-expression network analysis (WGCNA), functional enrichment (GO/KEGG), and immune infiltration deconvolution (CIBERSORT) were performed.

resultsBy multi-cohort analysis, 5 upregulated genes and 23 downregulated genes demonstrated prognostic significance in GBM. DENND2D was upregulated in high-grade gliomas (GBM > LGG; p < 0.05) and correlated with poor prognostic features (IDH-wildtype, non-1p/19q-codeletion). High DENND2D levels predicted worse survival (HR > 1, p < 0.001) in TCGA and CGGA cohorts. Expression was inversely correlated with promoter methylation (sites cg00619207/cg24641737) and was modulated by copy number alterations. WGCNA revealed co-expression with immune regulators (RAC2/TLR2/ITGB2/PTPRC/HLA-DPA1) and enrichment in leukocyte activation pathways (p < 0.01). CIBERSORT showed that DENND2D^high tumors had elevated immunosuppressive infiltrates: M1/M2 macrophages and γδ T cells in LGG, and M2 macrophages in GBM (p < 0.05).

conclusionDENND2D acts as an oncogene in glioma, driving aggressiveness and shaping an immunosuppressive microenvironment. It represents a novel prognostic biomarker and therapeutic target for overcoming immunotherapy resistance.

Indexed as

DENND2DGliomaImmunosuppressionPrognostic biomarkerTumor microenvironment

Identifiers

PMID41796401
PMCPMC13083557

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.